Idorsia Ltd (SWX:IDIA)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 569.40M |
| Revenue (ttm) | 217.22M |
| Net Income (ttm) | -133.30M |
| Shares Out | 204.09M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 653,943 |
| Average Volume | 1,345,187 |
| Open | 2.710 |
| Previous Close | 2.720 |
| Day's Range | 2.660 - 2.810 |
| 52-Week Range | 0.612 - 3.630 |
| Beta | 1.51 |
| RSI | 51.98 |
| Earnings Date | Oct 30, 2025 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat... [Read more]
Financial Performance
In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.
Financial StatementsNews
Invitation to Idorsia's aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call
Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension ther...
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sle...
Idorsia's TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endo...
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 19, 2025 Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204* million conve...
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025 Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204* million c...
Idorsia Ltd (IDRSF) Q2 2025 Earnings Call Transcript
Idorsia Ltd (OTC:IDRSF) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Andrew Jones - Senior VP, Head of Corporate Communications & Investor Relations Arno Groenewoud -...
Idorsia Ltd 2025 Q2 - Results - Earnings Call Presentation
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the sam...
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day.
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C.
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 m...
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
Ad hoc announcement pursuant to Art. 53 LR André C.
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and...
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Bo...
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia's path to profitability
Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026 Holistic convertible debt restructuring progressing...
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
Allschwil, Switzerland – May 2, 2025 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting t...
Idorsia publishes its Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report...
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
Allschwil, Switzerland – March 14, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in...
Idorsia Ltd (IDRSF) Q4 2024 Earnings Call Transcript
Idorsia Ltd 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Idorsia Ltd in conjunction with their 2024 Q4 earnings call.
Idorsia announces financial results for 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2024.
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia's outstanding convertible bond d...
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025 Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed...
Idorsia publishes the resolutions for the upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted upon Unaudited Financi...